Dianomi Therapeutics

About:

Dianomi Therapeutics company focused on developing treatments for inflammatory diseases, initially targeting osteoarthritis (OA).

Website: https://dianomitx.com/

Top Investors: Ligand Pharmaceuticals

Description:

Dianomi Therapeutics is a development stage biopharmaceutical company focused on improving the delivery and efficacy of large and small molecules in the treatment of inflammatory diseases. With an initial focus on osteoarthritis and rheumatoid arthritis, They are working to enhance the safety, efficacy, and duration of effect of therapeutic agents by incorporating them with Thier proprietary mineral coated microparticle system (MCM).

Total Funding Amount:

$3.19M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Parker, Colorado, United States

Founded Date:

2017-01-01

Founders:

Anna Clements, Barry Kurokawa, Carter Cliff, Martin Ostrowski, William L. Murphy

Number of Employees:

11-50

Last Funding Date:

2019-02-05

IPO Status:

Private

Industries:

© 2025 bioDAO.ai